Soluble receptor for advanced glycation end products (sRAGE) correlates with obesity-related parameters, and it is not easy to be modified by moderate caloric restriction in obese humans

Deficiency of a soluble form of the advanced glycation end products receptor (sRAGE) is implicated in obesity-induced complications. Serum sRAGE is inclined to be modified by changes in body weight. We analysed serum sRAGE concentrations in patients with obesity undergoing moderate calorie restriction, which mimics the real-life situation and is not harmful to obese humans. Serum sRAGE was measured by immunoassay in 50 patients with obesity who underwent calorie restriction by 300-500 kcal/day for 8 weeks. In effect calorie restriction resulted in an expected decrease in body weight (by 2.1 kg for an 8-week intervention, p<0.0001), as well as reduced systolic blood pressure, modified dyslipidemia (cholesterol, triglycerides), reduced obesity-related inflammation (tumor necrosis factor-alfa, interleukin-6, C-reactive protein), improved insulin sensitivity. However, it was not accompanied by any significant change in sRAGE concentration. There was a strong negative correlation between BMI and the sRAGE level. Accordingly, the levels of sRAGE were the highest in lean control. In conclusion: a modest weight reduction is unlikely to improve decreased sRAGE levels.

Chromogranin A as a useful neuroendocrine marker in patients with autoimmune Addison's disease

BACKGROUND

Antiparietal cells antibodies (APC-Ab) are commonly found in patients with autoimmune Addison's disease (AAD), usually pointing to autoimmune atrophic gastritis and pernicious anemia. The autoaggression to the gastric proton pumpmay result in a long-term hypergastrinemia, which predisposes to enterochromaffin-like cell hyper/dysplasia and gastric carcinoids.

AIM

We evaluated the clinical utility of assessing serum chromogranin A levels in patients with AAD.

MATERIAL AND METHODS

Serum chromogranin A, gastrin, and gastric APC-Ab levels were determined in 40 patients with AAD using commercially available kits.

RESULTS

Serum chromogranin A and gastrin levels were found to be elevated in 27.5 and 22.5% of patients with AAD, respectively. The Addison's patients with elevated APC-Ab had significantly higher chromogranin A and gastrin levels, as compared to individuals with normal APC-Ab (chromogranin A: 128.00+/-123.08 vs 57.68+/-36.50 ng/ml, p=0.0036; gastrin: 141.38+/-191.43 vs 49.50+/-75.36 muU/ml, p=0.003). Additionally, the patients with AAD and coexisting elevated serum APC-Ab, contrary to those with normal levels, showed a significant correlation between the chromogranin A and gastrin concentrations (r=0.52, p=0.0092 vs r=0.211, p=0.43). Serum chromogranin A appeared also significantly correlated with APC-Ab levels (r=0.431, p=0.005).

CONCLUSIONS

In patients with autoimmune Addison's disease hyperchromograninemia and hypergastrinemia occur with a prevalence of 27.5 and 22.5%, respectively. Addison's patients with coexisting elevated gastric APC-Ab, particularly with elevated gastrin levels, are at risk of enterochromaffin-like cells hyper/dysplasia. Serum chromogranin A assessment may complement histology for the early diagnosis of gastric carcinoid in these patients.

[Lipid mobilizing activity in blood serum during the follicular and luteal phases of the menstrual cycle]

The lipid mobilising activity of woman's blood serum in the follicular and luteal phases has been investigated. This activity was determined according to the Buckle method concerning parametrial adipose tissue of female rats. It was found to enhance the lipid mobilising activity in the follicular phase of the menstrual cycle. The increment of the lipid mobilising activity in the luteal phase was lower than in the follicular phase.

[Lovastatin in the treatment of hypercholesterolemia]

In 9 clinics 177 patients (68 men and 109 women) aged 23-69 years with primary hypercholesterolemia (TC above 6.5 mmol/L) were treated with lovastatin for 12 weeks. The treatment was started with 20 mg daily. The dose was doubled every 4 weeks, if the total serum cholesterol level did not fall below 5.2 mmol/L. For 4 weeks before treatment with lovastatin all patients received placebo. After the first 4 weeks of therapy the mean TC level decreased significantly (from 8.09 mmol/L to 6.54 mmol/L) by 18.5%. In comparison with the results after placebo (the starting value), after the 8 weeks of the therapy the TC level reduction reached 22.4% and after 12 weeks 23.5%. The mean LDL cholesterol decreased by 26.1%, 30.8% and 32.9% after 4.8 and 12 weeks of lovastatin treatment respectively. An increase in HDL cholesterol by 5.9%, 6.0% and 7.6% and decrease in triglyceride level by 10.7%, 14.9% and 14.0% respectively was also observed. In 6 patients on lovastatin treatment symptoms of acute pancreatitis in 1 case, a cataract in 1 case and aggravation of coronary insufficiency in 4 cases were noticed. These symptoms in the light of our knowledge of the mechanism of action of the drug used and of its side effects described in other trials, may be considered of independent on lovastatin. The treatment was discontinued in 5 cases (because of gastrointestinal intolerance in 2 patients, of aggravation of coronary insufficiency in 2 patients and of pain in the right hypochondrium in 1 patient who himself decided to stop the therapy).(ABSTRACT TRUNCATED AT 250 WORDS)

[Effect of compositional modification of coffee on certain indices of lipid metabolism in healthy volunteers and patients with hyperlipoproteinemia]

An effect of a 14-day drinking of coffee on some blood serum indices of lipid metabolism was investigated in 20 healthy volunteers and 20 patients with hyper lipoproteinemia (type IIb). The study was carried out in two subgroups: healthy volunteers or patients with hyperlipoproteinemia assigned to the first subgroup drank ordinary coffee and patients assigned to the second subgroup drank coffee deprived of irritant substances (4 glasses daily). It was found that ordinary coffee significantly increased total serum cholesterol and decreased serum HDL-cholesterol in healthy volunteers. Such effects were not seen in subgroup drinking coffee deprived of irritant substances. More significant increase in serum total cholesterol and decrease in serum HDL-cholesterol were found in patients with hyperlipoproteinemia. Drinking of modified coffee does not cause any significant changes in serum lipid metabolism. The authors concluded that drinking of the ordinary coffee should be restricted in patients with hyperlipoproteinemia and use of coffee deprived of irritant substances might be recommended to patients with this disease.

The effect of coffee deprived of irritant substances upon some indices of lipid metabolism in healthy volunteers and patients with hyperlipoproteinemia

Effect of 14 days coffee drinking upon some blood serum indices of lipid metabolism was studied on 20 healthy volunteers and 20 patients with hyperlipoproteinemia (type IIb). The study was done in two subgroups: healthy volunteers or patients with hyperlipoproteinemia which had belonged to the first subgroup drank ordinary coffee and the ones which belonged to the second subgroup drank coffee deprived of irritant substances. (4 glasses per day). It was found that in healthy volunteers ordinary coffee had given rise to a significant increase of serum total cholesterol and to a decrease of serum HDL-cholesterol. These changes were not observed in subgroup drinking coffee deprived of irritant substances. More significant rise of serum total cholesterol and decrease of serum HDL-cholesterol were found in patients with hyperlipoproteinemia. Drinking of modified coffee does not cause any significant changes in serum indices of lipid metabolism. The authors concluded that drinking of ordinary coffee should be restricted in patients with hyperlipoproteinemia and coffee deprived of irritant substances might be recommended to patients with this disease.

[Effect of tolbutamide on lipolytic processes in blood and fat tissue of rats maintained in normothermic and hypothermic conditions]

The effect of tolbutamide administered in vivo or added to the incubation medium on lipolysis in adipose tissue and in blood has been studied in rats. Tissue lipolysis was lowered by 118 to 156% in groups of rats receiving tolbutamide in vivo. The addition of tolbutamide directly to the incubation medium caused an increase in the lipid mobilizing activity, while the addition of insulin inhibited lipolysis in each case. The effect of tolbutamide administered in vivo may be indirect through an increase in insulin binding and/or the drug may influence directly the permeability of cell membrane for ions and glucose. An increase in the lipid mobilizing activity observed in experiments consisting in the addition of tolbutamide to the incubation medium may be linked to the low glucose level and greater demand for free fatty acids or to the low level of insulin in the incubation medium.

Triiodothyronine effect on some parameters of carbohydrate metabolism in rat blood and liver. I. In vivo effect of triiodothyronine on liver glycogen content, blood metabolites and serum glycogenolytic activity

Short (7 days) T3-treatment has no influence on the plasma glucose and FFA concentration and blood lactate level, as well as on the hepatic glycogen content in the rats. The rise in T3 levels, observed in our study, was accompanied by a fall in T4 concentrations, indicating suppression of the endogenous T4 production. On the other hand, glycogenolytic activity of rat serum in vitro is the highest in the system: control liver slices-serum of rats pretreated with T3 as compared to the system: control liver slices-control serum. These observations may lead to conclusions, that serum of rats pretreated with T3 contains factors exhibiting the greater ability to mobilize glucose from liver slices than the control serum (euthyroid). The possibility, that pretreatment with T3 may cause a decrease in the number and/or affinity of beta-adrenergic receptors in the rat liver, is discussed.